Arterial Disease Multifactorial Intervention Trial (ADMIT)

Summary

To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.

Timeline

Start

1992-09

Primary completion

—

Completion

1999-03

Publications

• Background Egan DA, Garg R, Wilt TJ, Pettinger MB, Davis KB, Crouse J, Herd JA, Hunninghake DB, Sheps DS, Kostis JB, Probstfield J, Waclawiw MA, Applegate W, Elam MB. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. Am J Cardiol. 1999 Feb 15;83(4):569-75. doi: 10.1016/s0002-9149(98)00915-1.
• Background Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 2000 Sep 13;284(10):1263-70. doi: 10.1001/jama.284.10.1263.
• Background Garg R, Elam MB, Crouse JR 3rd, Davis KB, Kennedy JW, Egan D, Herd JA, Hunninghake DB, Johnson WC, Kostis JB, Sheps DS, Applegate WB. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Am Heart J. 2000 Nov;140(5):792-803. doi: 10.1067/mhj.2000.110090.
• Background Chesney CM, Elam MB, Herd JA, Davis KB, Garg R, Hunninghake D, Kennedy JW, Applegate WB. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J. 2000 Oct;140(4):631-6. doi: 10.1067/mhj.2000.109648.

Drugs

Indications